CINXE.COM

<!DOCTYPE html><html lang="en-US"><head><title>Just a moment...</title><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta http-equiv="X-UA-Compatible" content="IE=Edge"><meta name="robots" content="noindex,nofollow"><meta name="viewport" content="width=device-width,initial-scale=1"><style>*{box-sizing:border-box;margin:0;padding:0}html{line-height:1.15;-webkit-text-size-adjust:100%;color:#313131;font-family:system-ui,-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Helvetica Neue,Arial,Noto Sans,sans-serif,Apple Color Emoji,Segoe UI Emoji,Segoe UI Symbol,Noto Color Emoji}body{display:flex;flex-direction:column;height:100vh;min-height:100vh}.main-content{margin:8rem auto;max-width:60rem;padding-left:1.5rem}@media (width <= 720px){.main-content{margin-top:4rem}}.h2{font-size:1.5rem;font-weight:500;line-height:2.25rem}@media (width <= 720px){.h2{font-size:1.25rem;line-height:1.5rem}}#challenge-error-text{background-image:url(data:image/svg+xml;base64,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);background-repeat:no-repeat;background-size:contain;padding-left:34px}@media (prefers-color-scheme:dark){body{background-color:#222;color:#d9d9d9}}</style><meta http-equiv="refresh" content="390"></head><body class="no-js"><div class="main-wrapper" role="main"><div class="main-content"><noscript><div class="h2"><span id="challenge-error-text">Enable JavaScript and cookies to continue</span></div></noscript></div></div><script>(function(){window._cf_chl_opt={cvId: '3',cZone: "aacrjournals.org",cType: 'managed',cRay: '8e901eba8cf1a8ee',cH: '4ve3IzboRRfS.lTjWa7nlLRK5fNCdUXGWDHMtRA6QJw-1732689555-1.2.1.1-81a5XRLaIW2Xt4.QcDji.BFMhd5qUo1amIZkMWeSA4POivXpEgluPq7.Z_NyBsxq',cUPMDTk: "\/mct\/article\/doi\/10.1158\/1535-7163.MCT-23-0809\/749717\/Tumor-Specific-Antigen-Delivery-for-T-cell-Therapy?__cf_chl_tk=oF9J0W0bXnz5vESlLRFZWVUDEO7xuynTKgzcDrH6py4-1732689555-1.0.1.1-.h6JuY_a.3e.bpy.v7VEBXGzT03u0_PP1GTzlRxNvSo",cFPWv: 'b',cITimeS: '1732689555',cTTimeMs: '1000',cMTimeMs: '390000',cTplC: 0,cTplV: 5,cTplB: 'cf',cK: "",fa: "\/mct\/article\/doi\/10.1158\/1535-7163.MCT-23-0809\/749717\/Tumor-Specific-Antigen-Delivery-for-T-cell-Therapy?__cf_chl_f_tk=oF9J0W0bXnz5vESlLRFZWVUDEO7xuynTKgzcDrH6py4-1732689555-1.0.1.1-.h6JuY_a.3e.bpy.v7VEBXGzT03u0_PP1GTzlRxNvSo",md: "fyVM1rPTNaRQ8EOEK5vVge4Oq6oYqeTYSUzIpX4OInc-1732689555-1.2.1.1-ZW4OuSz.X62o.ERI2U4k73gr8puzgyoTC.YzcuTxLxjmMK41riuX2lY1GBxf9phrY1uORQFV51dCYo3.hatGXPMEufw6xnIhojn9P09Ybkxk.KjbLwXkOmiy0thoS.gKBiA8OrlAvFCUyHhuGYdB1.DH14fnuCKdi9RJOTKQt8SIN1N3TyH_79KWRGEsJlQ9BcUYVBJ7MHOzlMjSmPzODhgXpGHBUHSwEMBSmSGC5lUokXqNSYzHt9ObjF50DNBASUzy1qN7M1JDtSmKFkeFZ9SBaEIxX9wwQ0h9xRFzk6JParTUcjo6sNTjzxbvd1TsReHTx2bJZt9wXN1yL7VHkPTETaQcYgjd45EPgTiduBtMSJ0Q7vmVKxg4i3TWkR1UuiEk_i_utJ1HQjOFDuKz_VXrmvY2FmV6vNhao8vYERXLkXED434001BEMkBMkY_JtKa.uJfFGcta90m.JEFQqC7Q5lnKtcjUsTbD6L2oXEM1ArV9c5a0RzvUefCV1oQNtHWZ4EOj.0l.BqsWvBDkzd6zfqxqJDCycSqCFfVZ9rjGser7ZieLWfJfgoDtK2lTnf58a74dt0urz8UO0XPjc.8N96agchbtYBX9NhgGPWU01CrsDrEFhBwbwAyGbBceiBJRxr1bYE0RCnUXRkzX4g3TpUJxajUxVWOHNZfzchItxxnla3JJTtePBAphV8EZwNd3alyeomAP2Ms3P8lMz2GyIoI8vrUqCxa9qasjET0R031WMrKQLPG7gsqrXQnfh4qzLyNC1jikMTcDtyiqhK1NDdnjd6jX0U0_yRta2XYJFNUb3O2nbfcH4R31f9s8po4_WQaqxQZJD6YDkumXpyLQxFiP44O.Lg8cLtPZNVHcrq1kQHMfrIVcJqzHwAbmogO01M7vrmwEsMdJrjfEKRlwPSvalZXLTm4cbEHb5CIEhuX58942W4UbvFfRVABBs8jM3e8cSHgYe0ABDkUhyrrTh13n8Ge2kMoD7eHZCmgi2uiSzpm2l0oYQLAq7LVj_uh7Iy1ZyEyLyU5jgxCIXMECaxgAoIYyxwsqGFstQDK_cvDMrefMErnFT.dyL25mk83TT_kijP2C2ny_iqOJnMD2qZJGboHi5uKnlqH6G6Qg7A1hWpVyi.l4aY8FwWCYgMT.pNfLF5qRZoWV8r0Y9q8SH7IXUG_06svxk8HWqJjOsggeeAwnvU..sy3NXs5pGk_ut6p326UUUKTWmQsQXjrXT3psPTJudCb6uHFGffo4L1miSVvkFOTnuYwDYkcNFpGseaW8p9tgPxxMlxtqHuRG92vEk71fwnVYb.gv3oWm4kp3WNmmv2rGntVxQQym6Mmlf.Hmg2lEwuRv0yICxglTT809eYTLh0ncfrzgmDhfrm6Y.UphJWYXTis.dPz17lUWhooG2erT_fIcT8GnJFv0zTCBxGfCSh5MJ1ZRYyT.wojWKG8YQShCxL7UzUlZ2EwPB_vKJhfeG4RDcpbitSG8D2UNOhl_2By7fEX3pl.xQ2EomFyA_VPmkXHl0c0woyn.Ui_HLtcPfXN7x4fYKyxfN3MRnIiNlWn5_d5msbL.9yf9N_h_tDnKZ6hqgO5LfrYzE8HJbwNhZCuRhuAQWaGwGaOKSPtNAdADh3DywGrQI2Jz33kaBT7peXlwpjfOXuibaO68u7vdrhOEwt0RtO4mI1609c4yixsJAKgIQLiXbgFLhtlzckmADNTegYXUvDlorJa7cVFcOcMkJdjhZaAUI7gYdUMzofDSKbqKMSU74vbub_FDkix2KieOb0_xWqAbMMNUExI7U2VtTuHXzRdjqctEIHZZb9DhePPugw2RH2qx73694zKY1Gn29UMwOpjmFgErQqka1dWgJazFyd8VdDb5O3tBo6BgHQrH0ZjvTCaEMhp5bL89k3SOzUaUdLMU.TquURqnJmkDBf4x5x3Ed19Or_H_Ra1_tfS.oicAYtTcydX0QwQe2T04BSRbVV_8TY.XBzzOsou9WjBJ5HujpLyAKLU5mo5zQ.10H4.MY1ECA7gb4tF4ERFHnVWdiZn4mW1aOQbNIbXK3cJSnU2bT_2Q3PEFAhRWhpu6HV_3IaYQ0F4fHDKb4_8SNXA154Oi_pFnH7svOksKtC2Bz0K7Tp0PoZWl.WlbnRpMhuVLzB4G4RwsRQ.Ihrto50ZASocAfHZNWvEvkCD_l.uw1VZnrxX0_d4mSBLFBl.iXgtpV4.PnlDsTKDP66WJXXA7rBeNp0RzV697Og2kzUtUokgNt31Eh4T0JuUco5E2qOxSkDPGAtMCacjLT2GuiWtbTi6R0kqI5mD_QQ6TQLU53ZvUTmRhGuF7Ptgl.EQ7CPJoAMV6dqHLXvekHzQpR6zeV.Fe7kxNlQbC9IuFzQbe3lgce6qXxueLYfgh55o1nOKZUvvSqw.4S5cpCr47VAPiPJzuTfpfEgxvG22XsyPqwh3kw.9C0M9HtnUrDiNDU3YSB_CdanSCANYpKu3TgGTEgvyAMwy_xDOQuL3ByiYjdRpqpu7Pl6mx3Ot6RZrdV.0KNwmx1wfgDHaa0ZMs.VaiPRx3tVt_ovO2XRRCA_l3BJZ_YaBzRiFzCmBojkc8u1z8bWhp_FuND9YNnrqHGjXBsEYbn2JT0V4u3CboTT6L9fOYGleOfBU6CS_5tSliFf4UrYkD1fIoKltLLWpO6NqzipWHRrsjveYHU.CU_ucLk28IafgQ7MTgP9Po274IG0i24i_bhnwshoHi_XBQw2wmIF9gtpt.YwDlpuvgs1dzvDiRpXs1ltR6XpqqBOnWvEdIDqznArZ7nEW66VyEUE2a6LVbjofNn3lpAIzHSBN4bHIgIGtyj5B5lCJ1h8qVWnwsQWec7yFU1Wjd47ScsOZvu1.9BFp6Y1tQyydHDrUXvRrUxYfCixNhCRlfWkmZDQwbIxWGAyCOSbkmQSKOtGf6dPThX5I8LxmRUwjYSly342uFc6Sgo__WHCfpyMGHQATIkAWH.J9uz9D4KBwommG_DlVD742s9C.YkNCLRQBOUPwC3VYJrcO0poXAGAVfS0bU0zNYJJiye2PhPdXD1zkUctxpcJes6nsGGzzhb4ZCyV7WbqpCBTX3E.x_SZWqa_2yFxKRkBseM332jVABgNco4DQcemAlNwsAsOtSRgdHlmqsCVznvzQfET49yLxMd4k",mdrd: "1WCZbmSmPdc4RbjOZ5Yf2eK.vGX0RZBcyNrqVJKoodM-1732689555-1.2.1.1-at9t5R6hbHFCmsn6ycGG_91Hj8pE9vF2C2exiveFLRgVCTpnUEZcMZH2f5Bb7nuBZRHkHDmOLJYWAJo9.QG_l4uyUsc6nYKjPwAU4gPmWWxghZX.FsK6BuXhI6bjRxzY30XKDODrdmVx4UpWkOOrvbKqCJ042umtn7m1DVNdMdgL9CDjaqQ9FU5EPQuIZ0efvpYehElBn6v8M.6zAS9zDu59TBTVQ4rCGdA3BUe7AjD0W3a0dXismlkvF2moRFxSWxRb.Kfgq4loYqADIvLN6PvxHZ0urF1vxOK7ijMU12a.boL88zvi1VQorcDgs2E.T.5uzGZqaZyY5PSuVuPcQ4hYhb1SLUozI3q0Dy5kD2jtA98RmklnR6eCyB.kepRa5mh61MUoNOd0R0UvvGm7JNdUU_DUfIOosgIgh7jFNyxVX9dPkMH__LiHTEeKBVFG4wLWO54jjtyqrN9f5EJZqyacG1jzX4h2rLHI77XANAPq9NAOUgMO4Mvmq6NfLOq0PCKFUA8d8jbJM3pS6JyUKAuuZQhXWhQIT4LfF.61Ly.URwmOfIsqDyTwyGxTj5fiVrD1NmyijyLXtVryBmFAIadOqdhw0rdTN7OqoRBdDr5mrJry1okaQZoH1GLbUTwonO5EvrK4OAAOu_Cns2hpGuHsctRYBuLJCg2bFOoJRXja9bOKby2XeaoNDQyJGhx0oe3LreJHSEBClBVlB_4OTd0iTShlUXmwkysNI4b7z.ovfL0Md3.GRfob1iYRLZZ4fEAuBb3zJWgtKQuN.ZFfhd55eAQ6RD0MlQHrnIh0bhmB9cS4F5lk30VZ.w40kZLGwFm6BWczhEvtEE3FaAT3qSTO8payMGyfhN7vFSQPVoRKvxPXRTbMFNQhJA9t2AE69Ao3aAXb_80K84Kmlu9RU8Nrsh.m02msh7HDeCmFyQyTa2g_fn0UasiBQzIKF35BnPOhKe5Zbo4yc51SiD7p_N98U2DzlqanpBbBGTSYxRjfw9nDBLkltfnpFj0LCX.bH9DyAipPTl9hNZHprVICp.sGOlbfyWZR9M0dkow4Z4UZrvHhPi.NLlhlQI_Y_Oh6HRpRieD9OB1JVtv5nrH0Ac9XaQxUtOQuGWFtjsb3IZglB0fv4jws7piDOkkSK4s_vHyFUDP8jHjZN7eLg22S6BD50skRpiiren2ra1mniQHcnb19vO7irb6AsJnqOSHDx5AzNKhP7MN52hl7E7nFOnexqClyFYtr.zJel7F0kRRCgHs9TogfqK.1hbgHWGy4TH5TT1KUwWlxa8pGjBugxTP5fDEhY09AnRC3G3eZB_gltIvBAYN7OrtY9nWPJhOorKNLWbkLC8fPrqsyWRtsbS7WhoPHtKxYRjc1xoOqAEsjU5Yvmgyc2cl5_qYOeKQIwf4yT.OGjTsJLobOTiRilDWhREYNE1oklP.ihbnQ47kGpKGUz_HagI0HoqnsnccTupKNN7tRpQz7uq6ZEz.eSNBsFDapuDDMx_NwC_ajxNF8OvpffN58qF6aPntzCYpD_V3NxH3qsNx..JOqIQwiJ11PjXBEeo5loRb.0rSbmJXIWelwIuPmMz0Jgafgw.bOfcqaYhymT5cMtJ4n0za3SOTDvTqh2Ygn7M2vHobpbnc5XaAm6aL7j63M_5IQgJKclp6CjZD3iOZDpjpTKPn0QPenGrBRpNoiPpzFJTXHBHBvDfcVnJ7eqcGhq52ZDZlf_op6GZNMSKzwtwSFPbyJ_SexQeTKjf0PFzTVzEnDwHj9LABj8iE571UmDfNXLd2qYq6mz90vGis1Skq1yWsFUnVqagit0H9zMQ7arYTM.bIs2CjmmdHt0B0YZAo0SfmsaqfFDLAC9WQeCA76OKJo94grK_d9Vw0tAgyZessazmKcXNGB..omjd4HSIaGr0PpIutfQxQJ5Bp0a.y73hSc8HVoC6iaXqbzyuPsvjYi.uUy_Qma7SCtu6p9vczDYZiS"};var cpo = document.createElement('script');cpo.src = '/cdn-cgi/challenge-platform/h/b/orchestrate/chl_page/v1?ray=8e901eba8cf1a8ee';window._cf_chl_opt.cOgUHash = location.hash === '' && location.href.indexOf('#') !== -1 ? '#' : location.hash;window._cf_chl_opt.cOgUQuery = location.search === '' && location.href.slice(0, location.href.length - window._cf_chl_opt.cOgUHash.length).indexOf('?') !== -1 ? '?' : location.search;if (window.history && window.history.replaceState) {var ogU = location.pathname + window._cf_chl_opt.cOgUQuery + window._cf_chl_opt.cOgUHash;history.replaceState(null, null, "\/mct\/article\/doi\/10.1158\/1535-7163.MCT-23-0809\/749717\/Tumor-Specific-Antigen-Delivery-for-T-cell-Therapy?__cf_chl_rt_tk=oF9J0W0bXnz5vESlLRFZWVUDEO7xuynTKgzcDrH6py4-1732689555-1.0.1.1-.h6JuY_a.3e.bpy.v7VEBXGzT03u0_PP1GTzlRxNvSo" + window._cf_chl_opt.cOgUHash);cpo.onload = function() {history.replaceState(null, null, ogU);}}document.getElementsByTagName('head')[0].appendChild(cpo);}());</script></body></html>